Only half a month after the clinical trial application was approved, the first subject was administered in the US Phase I clinical trial of ASC43F

SHANGHAI, Nov.

ASC43F is a fixed-dose single-tablet combination of 5 mg ASC41 (a thyroid hormone beta agonist) and 15 mg ASC42 (a farnesoid X receptor agonist) administered once daily

Phase I clinical trial data showed that ASC42 was safe and well tolerated, no pruritus symptoms were observed during the 14-day treatment period of 15 mg once daily, and low-density lipoprotein cholesterol levels were maintained during the treatment period

Animal studies showed that the pharmacokinetic parameters of ASC42 and ASC41A (active metabolites of ASC41) derived from ASC43F tablets were consistent with those of ASC42 and ASC41 single tablets

Dr.

Melissa Palmer, MD, Chief Medical Officer of Ganlai, said: "I am proud of the excellent execution of our clinical development team as we received FDA approval for this clinical trial nearly two weeks ago

About Song Li

Ascletis is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.

Viral diseases: (1) Hepatitis B (functional cure): Explore a treatment plan based on subcutaneous injection of PD-L1 antibody ASC22 and Pegasys® as cornerstone drugs, combined with other target drugs, which is expected to bring about functional cure of hepatitis B.